Clinical Curative Effect And Safety Of Milrinone Combined With Cedilanid In Patients With Congestive Heart Failure

Subjects: To evaluate the clinical efficacy and safety in congestive heartfailure patients using10mg milrinone combined with0.2mg cedilanid bycomparing with the group using0.2mg cedilanid as contrast drug only.Methods: The controlled experiment was applied randomly and cedilanidworked as the positive drug. All congestive heart failure patients who fit theinclusion criteria were randomly divided into trial group (milrinone combinewith cedilanid) and control group (cedilanid). The trial group was treated with10mg milrinone and0.2mg cedilanid:3mg milrinone was diluted to20ml andintravenous injected slowly in10minutes as loading dose;7mg milrinone wasdiluted to100ml and intravenous transfused constantly in3hours as maintaindose;0.2mg cedilanid was diluted to20ml and intravenous injected slowly in10minutes. The control group was treated with0.2mg cedilanid injection fluid:0.2mg cedilanid was diluted to20ml and intravenous injected slowly in10minutes. Both groups were treated once a day for5days. All patients’ clinicalsymptoms and signs before and after treatment were recorded; echocardiography,NT-ProBNP and biochemistry indicators results were obtained. All adverse reactions during treatment were recorded. The data were statistically analyzed inthe end.Results: According to NYHA cardiac function classification curative effectevaluation, the effective rate of trial group is97.14%and control group is87.88%. There is no statistical significance between the two groups (P>0.05).The LVEF of trial group is35.43%±12.19%, before the treatment and42.84%±6.49%after the treatment; Comparisons in the group before and after thetreatment were statistically significant (P<0.01)；the control group is32.65%±10.38%and37.91%±10.93%respectively. Comparisons in the group beforeand after the treatment were statistically significant (P<0.05), and statisticalsignificance also exists between two groups before and after the treatment(P<0.05). The NT-proBNP value in trial group is8070.00(4570.00,11200.00)ng/ml before the treatment and1380.00(1090.00,1620.00) ng/ml after thetreatment; in control group is7560.00(3320.00,9590.00) ng/ml and2210.00(1120.00,7170.00) ng/ml respectively. There is statistical significance ingroup before and after the treatment as well as between the two groups (P<0.01).There is no statistical significance between the two groups when comparingliver function (ALT, AST), kidney function (creatinine, urea nitrogen) andelectrolytes (potassium iron, sodium iron, chloride iron and calcium iron)(P>0.05).Conclusion: Comparing with the cedilanid (0.2mg), a short-term use ofmilrinone (10mg) combined with cedilanid (0.2mg) will improve the patients’ clinical symptoms and cardiac function significantly, and NT-ProBNP level canbe reduced.